

This is a CLIA Waived Test

WARNING: Read the Directional Insert prior to performing the test.



10 min.

17°–37°C

(62.6°–98.6° F)



a) **Positive Result:**
A blue or green color in the BV Test Vessel or on the head of the swab.

b) **Negative Result:**
A yellow color in the BV Test Vessel.

Collect a vaginal fluid sample with a swab. Contact the swab with the lower one-third of the vaginal wall. Collect as much fluid as possible. Put the swab into the BV Test Vessel. Gently swirl the mixture.

Let the BV Test Vessel containing the swab stand for 10 minutes between 17° and 37°C.

Add one drop of Developer Solution to the BV Test Vessel containing the swab.

Gently swirl the mixture. Read the results immediately.

CAUTION: The Developer Solution is a dilute alkaline solution. This may cause skin and eye irritation. If the solution comes in contact with the skin or eyes, flush with large volumes of water.

POSITIVE NEGATIVE

INTERPRETATION OF TEST RESULTS:
There are two possible results:
(a) positive result or (b) negative result

NOTE: You may need to remove the swab to read the test results.

A Positive Result shows a high level of sialidase activity. A Negative Result shows a normal level of sialidase activity.

For facilities in the US: A CLIA Certificate of Waiver is needed to perform testing in waived settings. Read all instructions carefully before use. If a laboratory modifies the following test instructions including Quality Control, the test will be considered High Complexity and no longer considered Waived.

WARNINGS AND PRECAUTIONS:

- For *In Vitro* diagnostic use only.
- Do not use after the expiration date printed on the kit.
- Do not store the kit at temperatures above 26°C (79°F).
- Do not store the kit in strong light.
- Follow your laboratory safety guidelines in the collection, handling, storage and disposal of patient specimens and all items exposed to patient specimens.
- Used tests should never be re-used.
- This product is intended for vaginal fluid use only.
- Do not use samples from patients who have used vaginal cream products within 72 hours before testing.
- Do not touch or collect fluid near the cervix.

STORAGE AND STABILITY:

Store the kit at controlled temperature, 2°-26°C (36°-79°F), out of direct sunlight. Store vessels inside the box. Kit contents are stable until the expiration date printed on the outer box.

NOTE: If temperatures in your facility may exceed 26°C (79°F), the kit should be refrigerated when not in use to ensure that the components remain stable until the expiration date printed on the packaging. **Allow the kit to come to room temperature before running the test.**

LIMITATIONS OF THE PROCEDURE:

- Do not use samples from the cervix.
- Patients may have mixed infections. The OSOM BVALUE Test shows that stailidase enzyme is active in the sample. The OSOM BVALUE Test does not show if other organisms such as yeast and parasitic organisms are present in the sample.
- Test results should be considered in conjunction with other clinical and patient information.
- Test operators must follow all instructions to

- a) collect the sample
 - b) store the sample and
 - c) use the test procedure properly
- If the instructions are not followed, the OSOM BVALUE Test may not give correct results.

QUALITY CONTROL:

1. Internal Quality Controls

The OSOM BVALUE Test contains two types of internal quality control with each test run. For daily quality control, the manufacturer recommends documenting these controls on each day of testing:

- Type 1 Control: Before adding a patient specimen, inspect the Test Vessel. It should contain a colorless liquid without precipitates (sediment).

If the testing vessel contains a precipitate, the test is invalid. Do not use the Test Vessel.

- Type 2 Control: The OSOM BVALUE Test has a two-color result format: blue/green is positive, yellow is negative. After running the test according to the instructions for use, the appearance of either a uniform yellow, blue, or green color in the testing vessel or a blue or green color on the swab assures proper mixing of the reagent and sample has occurred.

If the test fails to provide either a blue, green, or a yellow color result, the test is invalid.

- Do not report patient results if either of the Internal Quality Controls does not produce expected results.

2. External Quality Controls

External Controls are used to test that the reagents are working properly. Also use the Controls to test that you are able to correctly perform the test procedure.

- A Control Kit that contains a positive control and a negative control may be purchased separately from Genzyme Diagnostics Catalog No. 184.
- Refer to the Control Kit Directional Insert for instructions on how to interpret the results of the controls.

If QC testing fails:

- Check expiration dates of the test kit and controls
- Ensure the instructions for testing were followed
- Repeat the test

If the controls still do not perform as expected, contact Genzyme Technical Service at 1-800-332-1042.

You should follow the manufacturer's guidelines for QC testing. These guidelines state that external controls be run with each new lot, each new shipment and with each new untrained operator.

OSOM

BVBLUE® Test

This is a CLIA Waived Test

For facilities in the US: A CLIA Certificate of Waiver is needed to perform testing in waived settings. Read all instructions carefully before use. If a laboratory modifies the following test instructions including Quality Control, the test will be considered High Complexity and no longer considered Waived.

INTENDED USE:

The OSOM BVBLUE Test is an enzyme activity test for use in the detection of vaginal fluid specimens for sialidase activity, an enzyme produced by bacterial pathogens such as *Gardnerella vaginalis*, *Bacteroides spp.*, *Prevotella spp.*, and *Mobiluncus spp.*

The OSOM BVBLUE Test is indicated for use in women suspected of having Bacterial Vaginosis (BV) infection, e.g., women with vaginal discharge typical of BV and/or women with previous history of BV, as an aid in the diagnosis of BV infection. Test results should be considered in conjunction with other clinical and patient information (see Limitations of the Procedure).

For *In Vitro* Diagnostic Use Only. The OSOM BVBLUE Test is indicated for professional use only and may be used at the point of care and/or in physician's offices. It is not intended for home use.

SUMMARY AND EXPLANATION OF THE TEST:

Vaginitis is one of the most common reasons that women visit obstetricians or gynecologists¹⁻³. BV is the most common form of infectious vaginitis. The causative agents of the infection are bacterial pathogens such as *Gardnerella vaginalis*, *Bacteroides spp.*, *Prevotella spp.* and *Mobiluncus spp.*

Complications associated with BV include salpingitis, endometritis, post-hysterectomy infections, recurrent UTI's, and an increased risk of PID and HIV⁶⁻⁷. BV presents a serious danger in women, due to its significant association with placental infection, premature rupture of membranes, and preterm birth⁸⁻¹⁰.

Studies have shown elevated sialidase activity in women with BV and an increased risk for preterm birth and low birth weight infants in patients exhibiting elevated sialidase activity^{4,11-15}.

The OSOM BVBLUE Test is designed to provide a clear, simple indication of elevated sialidase activity in patient vaginal fluid samples. The generation of a blue or green color indicates a positive test result; a yellow color indicates a negative test result.

PRINCIPLES OF BVBLUE:

The OSOM BVBLUE Test includes a chromogenic substrate of bacterial sialidase. In the test procedure, a vaginal fluid sample is placed in the BV Test Vessel. The sample then reacts with the chromogenic substrate. A Developer Solution is added after the reaction.

If the sample has a high level of sialidase, a blue or green color will be seen in the BV Test Vessel or on the head of the swab. If the sample has no sialidase, or has very low levels, a yellow color will be seen in the BV Test Vessel.

REAGENTS / MATERIALS:

- IBX-4041 component (0.25 mg/test)
- potassium acetate (24.5 mg/test)
- sodium hydroxide (1.0 mg/test)

Materials Provided:

- 25 Test Vessels each containing 0.25 mg IBX-4041 component in 0.5 mL of an aqueous potassium acetate buffer solution (49mg/mL; 0.5 M; pH 5.5-6.0)
- 1 Developer Solution Bottle containing 10.0 mL of an aqueous sodium hydroxide solution (40mg/mL; 1.0 M; pH>11.0)
- Sterile Swabs
- 1 Directional Insert

Materials Required But Not Provided:

- OSOM BVBLUE Control Kit
- Timer

WARNINGS AND PRECAUTIONS:

- For *In Vitro* diagnostic use only.
- Do not use after the expiration date printed on the kit.
- Do not store the kit at temperatures above 26°C (79°F).
- Do not store the kit in strong light.
- Follow your laboratory safety guidelines in the collection, handling, storage and disposal of patient specimens and all items exposed to patient specimens.
- Used tests should never be re-used.
- This product is intended for vaginal fluid use only.

SPECIMEN COLLECTION AND STORAGE:

- Collect specimens with a swab from the lower one-third of the vaginal wall. Collecting specimens from the cervix should be avoided because (a) it might increase risk to OB patients, and (b) cervical sialidase activity is usually higher than vaginal sialidase activity.
- Do not use specimens from patients who have (a) used a vaginal cream or ointment product, (b) douched, or (c) used spermicides, vaginal lubricants or feminine sprays within 72 hours of testing.
- Test the patient specimen as soon as possible after collection.
- If you do not perform the OSOM BVBLUE test immediately, store the swabs either at room temperature for up to 48 hours or refrigerated for up to 7 days. To transport patient specimens, place each swab in a clean, dry container such as a plastic or glass tube. Do not use any transport media.
- If you do not collect enough sample or collect from a patient undergoing antimicrobial therapy the test may give a false negative result.

STORAGE AND STABILITY:

Store the kit at controlled temperature, 2°-26°C (36°-79°F), out of direct sunlight. Store vessels inside the box. Kit contents are stable until the expiration date printed on the outer box.

NOTE: If temperatures in your facility may exceed 26°C (79°F), the kit should be refrigerated when not in use to ensure that the components remain stable until the expiration date printed on the packaging. **Allow the kit to come to room temperature before running the test.**

INDICATIONS OF INSTABILITY:

Signs of possible product instability include:

- A blue color in a BV Test Vessel when one drop of Developer Solution is added to the BV Test Vessel in the absence of a patient specimen.
- Positive control does not give expected results.
- Negative control does not give expected results.

QUALITY CONTROL:

1. Internal Quality Controls

The OSOM BVBLUE Test contains two types of internal quality control with each test run. For daily quality control, the manufacturer recommends documenting these controls on each day of testing:

- Type 1 Control: Before adding a patient specimen, inspect the BV Test Vessel. It should contain a colorless liquid without precipitates (sediment).

If the testing vessel contains a precipitate, the test is invalid. Do not use the BV Test Vessel.

- Type 2 Control: The OSOM BVBLUE Test has a two-color result format: blue/green is positive, yellow is negative. After running the test according to the instructions for use, the appearance of either a uniform yellow, blue, or green color in the testing vessel or a blue or green color on the swab assures proper mixing of the reagent and sample has occurred.

If the test fails to provide either a blue, green, or a yellow color result the test is invalid.

Do not report patient results if either the Type 1 Control or the Type 2 Control does not produce expected results.

2. External Quality Controls

External Controls (available from Genzyme), are used to test that the reagents are working properly. Also use the Controls to test that you are able to correctly perform the test procedure.

- A Control Kit that contains a positive control and a negative control is available from Genzyme Diagnostics and may be purchased separately, Catalog No. 184.
- Refer to the Control Kit Directional Insert for instructions on how to interpret the results of the controls.

If QC testing fails:

- Check expiration dates of the test kit and controls
- Ensure the instructions for testing were followed
- Repeat the test

If the controls still do not perform as expected contact Genzyme Technical Service at 1-800-332-1042.

2a. For CLIA Waived Labs

You should follow the guidelines below for QC testing. The manufacturer recommends that external controls be run with each new lot, each new shipment and with each new untrained operator.

2b. For CLIA Non-Waived Labs

Quality Control requirements should be established in accordance with local, state and federal regulations or accreditation requirements. Minimally, the manufacturer recommends that external controls be run with each new lot, each new shipment and with each new untrained operator.

LIMITATIONS OF THE PROCEDURE:

- Do not use samples from the cervix.
- Patients may have mixed infections. The OSOM BVBLUE Test shows that sialidase enzyme is active in the sample. The OSOM BVBLUE Test does not show if other organisms such as yeast and parasitic organisms are present in the sample.
- Test results should be considered in conjunction with other clinical and patient information.
- Test operators must follow all instructions to a) collect the sample, b) store the sample, and c) use the test procedure properly. If the instructions are not followed, the OSOM BVBLUE test may not give correct results.

EXPECTED VALUES:

The OSOM BVBLUE Test can show sialidase activity in vaginal fluid at levels of $\geq 7.8U$. There are two possible results; positive or negative. If the test fails to provide a blue, green, or yellow color result, the test is invalid.

INSTRUCTIONS FOR USE:

STEP 1

Remove one BV Test Vessel and the Developer Solution Bottle from the kit prior to use. Remove the cap from the BV Test Vessel.

STEP 2

Collect a vaginal fluid sample with a swab. Contact the swab with the lower one-third of the vaginal wall. Collect as much fluid as possible.

NOTE: Do not use samples from patients who have used vaginal cream products within 72 hours before testing. Do not touch or collect fluid near the cervix.

STEP 3

Put the swab into the BV Test Vessel. Gently swirl the mixture.

STEP 4

Let the BV Test Vessel containing the swab stand for 10 minutes between 17° and 37°C. (62.6°- 98.6°F).

STEP 5

Add **one** drop of Developer Solution to the BV Test Vessel containing the swab. Gently swirl the mixture. **Read the results immediately.**

CAUTION: The Developer Solution is a dilute alkaline solution. This may cause skin and eye irritation. If the solution comes in contact with the skin or eyes, flush with large volumes of water.

INTERPRETATION OF TEST RESULTS:

There are two possible results: (a) positive result or (b) negative result.

a) Positive Result: A blue or green color in the BV Test Vessel or on the head of the swab.

b) Negative Result: A yellow color in the BV Test Vessel.

NOTE: You may need to remove the swab to read the test results.

A Positive Result shows a high level of sialidase activity.

A Negative Result shows a normal level of sialidase activity.






TABLE 1. RESULTS OF A STUDY OF 118 WOMEN

Patient Type	Mean Vaginal Fluid Sialidase Activity
Patients with BV	12.3 U (95% CI 8.1-16.6 U)
Healthy Controls	2.7 U (95% CI 2.2-3.2 U)
Patients with Candidiasis	3.7 U (95% CI 2.6-4.8 U)
Patients with Trichomoniasis	1.99 U (95% CI 0.6-3.4 U)

PERFORMANCE CHARACTERISTICS:**MINIMUM DETECTION LIMIT (MDL):**

The OSOM BVBLUE Test was evaluated by different users using control samples to demonstrate the MDL of 0.3 µg (7.8 U). A total of 64 samples with sialidase levels above the MDL were evaluated. Complete agreement of results was obtained on every sample. A total of 233 samples with sialidase levels below the MDL were evaluated. Complete agreement of results was obtained on 99% of samples.

REPRODUCIBILITY STUDIES:

The OSOM BVBLUE Test was evaluated at three clinics by three different users (MLTs and RNs) for reproducibility within and between runs and clinics. Each site evaluated 5 coded control samples in triplicate on each of 3 days. A total of 45 samples were evaluated by each clinic. Three of the 5 samples were positive samples and 2 were negative samples. Complete agreement of results was obtained on every sample by each of the three sites, demonstrating the inter-operator, inter-site, intra-site, and inter-day reproducibility of the test.

The OSOM BVBLUE Test was evaluated at three clinics by three different users (MLTs and RNs) for reproducibility within and between runs and clinics. Each site evaluated 10 coded clinical samples over 3 days. Six of the 10 samples were positive samples and 4 were negative samples. Complete agreement of results was obtained on every sample by each of the three sites, demonstrating the inter-operator, inter-site, intra-site, and inter-day reproducibility of the test.

INTERFERENCE STUDIES:

In all clinical studies, no evidence of interference was observed for menses (n=118); blood (n=620); semen (n=620); birth control methods (n=36) including birth control pills, Depo-Provera, Norplant, IUDs, condoms, or tubal ligation; or microorganisms (n=118) including Staphylococcus, Streptococcus, E. coli, Candida albicans, Lactobacillus, among others.

METHOD COMPARISON:

The OSOM BVBLUE Test was evaluated at five clinics by different users (MDs, MLTs, and RNs) in the US. A total of 620 women were evaluated. Patients treated with a vaginal cream or ointment product within 72 hours prior to testing were excluded.

Independent investigators evaluated the performance of the OSOM BVBLUE Test compared to Amsel Criteria in 620 women (TABLE 2). A clinical diagnosis of BV required the following three symptoms: vaginal fluid pH > 4.5, the presence of vaginal fluid amines, and the presence of clue cells (>20%). Of the 164 symptomatic women, 65% were diagnosed with BV. Of the 456 asymptomatic women, <1% were diagnosed with BV. The sensitivity and specificity of OSOM BVBLUE compared to Amsel Criteria was found to be 85.2% and 89.6% respectively.

Independent investigators evaluated the performance of OSOM BVBLUE compared to Gram's stain in 118 women (TABLES 3 and 5). A clinical diagnosis of BV required a Gram's stain score of 7-10¹⁰. Of the 27 symptomatic women, 78% were diagnosed with BV. Of the 91 asymptomatic women, 11% were diagnosed with BV. The sensitivity and specificity of OSOM BVBLUE compared to Gram's stain was found to be 90.3% and 96.6% respectively.

Independent investigators evaluated the performance of OSOM BVBLUE compared to Gram's stain in 220 women (TABLE 6). The sensitivity and specificity of OSOM BVBLUE compared to Gram's stain was found to be 92.8% and 98.0%, respectively.

TABLE 2. UNRECONCILED PERFORMANCE OF OSOM BVBLUE COMPARED TO AMSEL CRITERIA

	BVBLUE Positive
All patients tested (n = 620) (P < 0.0001)	145 (23.4%)
Results in patients with BV by Amsel Criteria (n = 108)	92 (85.2%)
Results in patients without BV by Amsel Criteria (n = 512)	53 (10.4%)

TABLE 3. UNRECONCILED PERFORMANCE OF OSOM BVBLUE COMPARED TO GRAM'S STAIN

	BVBLUE Positive
All patients tested (n = 118) (P < 0.0001)	31 (26.3%)
Results in patients with BV by Gram's Stain (n = 31)	28 (90.3%)
Results in patients without BV by Gram's Stain (n = 87)	3 (3.4%)

MIXED INFECTIONS:

The OSOM BV_{BLUE} Test was investigated in 255 patients stratified by clinical diagnosis. The results of this study are presented in TABLE 4.

TABLE 4. RESULTS OF OSOM BV_{BLUE} IN PATIENTS STRATIFIED BY CLINICAL DIAGNOSES

No. of Patients	Clinical Diagnosis			BV _{BLUE} Positive
	Amsel Criteria	Wet Mount		
	BV	Yeast	Tric	
0	+	+	+	0
5	+	+	-	4
2	+	-	+	2
0	-	+	+	0
4	-	-	+	0
41	-	+	-	0
50	+	-	-	48
153	-	-	-	9
Total (255)	57	46	6	63

TABLE 5. PERFORMANCE OF OSOM BV_{BLUE} AND EIGHT OTHER CLINICAL METHODS COMPARED TO GRAM'S STAIN RESULTS IN 118 PATIENTS.

Test vs. Gram's Stain	Sensitivity (%)	Specificity (%)	Overall Accuracy (%)
All patients (n = 118)			
OSOM BV _{BLUE}	90.3	96.6	94.9
Amsel Criteria	58.1	95.4	85.6
Vaginal Fluid pH ^a (n = 117)	90.3	65.1	71.8
Vaginal Fluid Amines (n = 117)	67.7	93.0	86.3
Vaginal Fluid pH and Vaginal Fluid Amines ^b (n = 117)	67.7	94.2	86.4
Wet Prep (>20% clue cells) (n = 117)	71.0	89.5	84.6
Wet Prep (any clue cells) (n = 117)	77.4	84.9	82.9
Semiquantitative Identification of Morphotypes Associated with BV ^c	100	86.2	89.8
Clinically Significant Culture of Microorganisms Associated with BV ^d (n = 55)	55.6	86.5	76.4

^aVaginal fluid pH > 4.5 considered positive result.

^bVaginal fluid pH > 4.5 and presence of vaginal fluid amines considered positive result.

All other combinations considered negative result.


^cIncludes identification and scoring of *Gardnerella vaginalis*, *Bacteroides* spp., *Prevotella* spp., and/or *Mobiluncus* spp. using Gram's stain. Score of 1+ considered positive result for *Mobiluncus* spp.

All other morphotypes required score of 3+.

^dIncludes typing and scoring of *Gardnerella vaginalis*, *Bacteroides* spp., and/or *Prevotella* spp.

Score of 2+ for each microorganism considered positive result.

FIGURE 1. ASSOCIATION BETWEEN GRAM'S STAIN SCORE AND TEST RESULTS FROM OSOM BV^{BLUE} AND AMSEL CRITERIA^a



^aGram's stains scored using Nugent method¹³.

TABLE 6. PERFORMANCE OF OSOM BV^{BLUE} COMPARED TO GRAM'S STAIN

Sample Type	Correct	Incorrect	Agreement (95% CI)
All patients tested (n = 220) (P<0.0001)	212	8	96.4% (93.9-98.8%)
Results in patients with BV by Gram's Stain (n=69)	64	5	92.8% (86.6-98.9%)
Results in patients without BV Gram's Stain (n=151)	148	3	98.0% (95.8-100%)

CLIA WAIVER PERFORMANCE:

The OSOM BV^{BLUE} Test was evaluated by seventy-five non-trained operators at three non-clinical lab sites. Each operator at each site tested four samples from a randomly coded panel of strong negative (25), weak negative (25), weak positive (25), and strong positive samples (25). Three trained lab operators at one lab site ran all 300 samples. Agreement among non-trained operators and known sample distribution was as follows:

TABLE 7. CLIA WAIVER PERFORMANCE OF OSOM BV^{BLUE}

Sample (sialidase activity)	Agreement
Strong Negative (0.15 U)	98.7%
Weak Negative (6.08 U)	100%
Weak Positive (9.15 U)	100%
Strong Positive (20.1 U)	100%

REFERENCES:

1. Hillier, S.L. Diagnostic microbiology of bacterial vaginosis. *Am. J. Obstet. Gynecol.* **1993**; 169:455.
2. Eschenbach, D.A. History and review of bacterial vaginosis. *Am. J. Obstet. Gynecol.* **1993**; 169:441.
3. Hill, G.B. The microbiology of bacterial vaginosis. *Am. J. Obstet. Gynecol.* **1993**; 169:450.
4. Briselden, A.N.; *et al.* Sialidases (neuraminidases) in bacterial vaginosis and bacterial vaginosis-associated microflora. *J. Clin. Microbiol.* **1992**; 30:663.
5. Faro, S.; *et al.* vaginal flora and pelvic inflammatory disease. *Am. J. Obstet. Gynecol.* **1993**; 169:47
6. Taha, T.E.; *et al.* HIV infection and disturbances of vaginal flora during pregnancy. *J. Acquired Imm. Def. Syndr.* **1999**; 20:52.
7. Royce, R.A.; *et al.* Bacterial vaginosis associated with HIV infection in pregnant women from North Carolina. *J. Acquired Imm. Def. Syndr.* **1999**; 20:382.
8. Chiam, W.; *et al.* The relationship between bacterial vaginosis and preterm birth. A review. *Arch. Gynecol. Obstet.* **1997**; 259:51
9. McGregor, J.A.; *et al.* Premature rupture of membranes and bacterial vaginosis. *Am. J. Obstet. Gynecol.* **1993**; 169:463.
10. Leitch, H.; *et al.* Bacterial vaginosis as a risk factor for preterm delivery: A meta-analysis. *Am. J. Obstet. Gynecol.* **2003**; 189:139.
11. McGregor, J.A.; *et al.* Bacterial vaginosis is associated with prematurity and vaginal fluid mucinase and sialidase: Results of a controlled trial of topical clindamycin cream. *Am. J. Obstet. Gynecol.* **1994**; 170:1048.
12. Cauci, S.; *et al.* Immunoglobulin A response against *Gardnerella vaginalis* hemolysin and sialidase activity in bacterial vaginosis. *Am. J. Obstet. Gynecol.* **1998**; 178:511.
13. Andrews, A.A.; *et al.* The preterm prediction study: failure of midtrimester cervical sialidase level elevation to predict subsequent spontaneous preterm birth. *Am. J. Obstet. Gynecol.* **1999**; 180:1151.
14. Cauci, S.; *et al.* Determination of Immunoglobulin A against *Gardnerella vaginalis* hemolysin, and with prolidase and sialidase levels in women with bacterial vaginosis. *J. Infect. Dis.* **2002**; 185:1614.
15. Cauci, S.; *et al.* Determination of Immunoglobulin A against *Gardnerella vaginalis* hemolysin, sialidase, and prolidase activities in vaginal fluid: Implications for adverse pregnancy outcomes. *J. Clin. Microbiol.* **2003**; 41:435.
16. Nugent, R.P.; *et al.* Reliability of diagnosing bacterial vaginosis is improved by a standardized method of Gram stain interpretation. *J. Clin. Microbiol.* **1991**; 29:297.

ASSISTANCE

For technical assistance call Genzyme Diagnostics Technical Service at 800-332-1042.

RE-ORDER

No. 183 OSOM® BVBLUE® (25 Tests)

No. 184 OSOM® BVBLUE® Control Kit

Manufactured by Gryphus Diagnostics, LLC.

BVBLUE® is a registered trademark of Gryphus Diagnostics, LLC.

U.S. Patent nos 6,512,100;6,667,161;6,812,332. Other patents pending.

OSOM® is a registered trademark of Genzyme Diagnostics.

KEY TO COMPONENT LABELING



Use by YYYY-MM



Batch code



Catalog number



Contents sufficient for <n> tests



In vitro diagnostic medical device



Temperature limitation



Consult instructions for use



Authorized representative
in the European Community

MANUFACTURED FOR:

genzyme

Diagnostics

Cambridge, MA 02139

Tel: 800-332-1042

617-252-7760

Fax: 617-252-7759

www.genzymediagnosics.com